Moderna
MRNA · NASDAQ · Biotech · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$1.9B
Net margin
-145.2%
ROE
-32.6%
Revenue CAGR (2y)
-46.7%
EPS (FY2025)
-7.26
Net profit (FY2025)
$-2.8B
Ask MarketChacha about MRNA
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Sep 11, 2026
Moderna rose about 8.6% in volatile trading without a single fresh company announcement; coverage attributed the move to momentum and a risk-on market, while peers BioNTech and Merck were flat.
- Sep 1, 2026
Moderna shares rose on continued momentum from late-August Phase 3 success for its personalized mRNA cancer vaccine (intismeran autogene) with Merck in high-risk melanoma, which met primary and key secondary endpoints and is reshaping the company's oncology outlook; the formal close of its upsized $2.6B convertible notes offering also supported sentiment.
source 1 ↗· confidence: high - Aug 25, 2026
Moderna shares rose sharply on fresh analyst upgrades (including Wolfe Research today) building on the landmark positive Phase 3 INTerpath-001 oncology data announced August 19 with Merck for its personalized mRNA cancer vaccine in melanoma.
- Aug 20, 2026
Moderna gave back a large part of the prior session's record surge as traders took profits. The stock had rocketed on Wednesday after Moderna and Merck reported that their personalised mRNA cancer vaccine combined with Keytruda met its targets in a Phase 3 melanoma trial.
source 1 ↗· confidence: high - Jul 20, 2026
No specific company catalyst or filing identified for the July 20 move; Moderna shares moved lower alongside broader market or sector weakness as noted in recent market summaries.
- Jul 16, 2026
Moderna shares tumbled with no clear company-specific catalyst identified, consistent with profit-taking in biotech names after recent gains and sector rotation.
source 1 ↗· confidence: low - Jul 10, 2026
Moderna shares fell sharply after JPMorgan reaffirmed its Sell rating and included the stock on a list of 25 names to short into Q3, citing that recent gains had already priced in pipeline success such as the Merck melanoma partnership.
source 1 ↗· confidence: high - Jul 9, 2026
Moderna shares rose on positive analyst actions including price target increases from Morgan Stanley, BofA, and RBC Capital, alongside news of a new board appointment (Michael McDonnell) disclosed in the July 8 8-K and a recent EU contract for up to 24 million RSV vaccine doses.
- Jul 8, 2026
Moderna shares fell as investors took profits following a sharp June rally that delivered nearly 50% gains, with momentum fading and no major negative catalyst reported.
source 1 ↗· confidence: medium - Jul 2, 2026
Moderna shares rose on positive pipeline updates and encouraging flu vaccine data that lifted sentiment, per multiple July 2 reports; the move continued momentum from recent FDA-related developments.
- Jul 1, 2026
Moderna shares rose on continued momentum from its late-June mRNA pipeline update and positive FDA advisory committee vote on the mRNA-1010 flu vaccine, with no new company-specific catalyst reported for July 1.
- Jun 29, 2026
Moderna shares continued their recent rally on ongoing investor optimism around its cancer pipeline, CAR-T efforts, and plans to expand the mRNA platform beyond vaccines into oncology and other areas, per multiple market reports.
- Jun 26, 2026
Moderna shares surged on optimism from its June 25 Science Day updates highlighting pipeline expansion into oncology and autoimmune diseases, including in vivo CAR-T (mRNA-6007) and T-cell engager programs, plus recent FDA advisory support for its flu vaccine.
- Jun 22, 2026
Moderna shares fell after snapping a six-day rally driven by recent positive FDA flu vaccine updates, amid broader market pressures weighing on biotech stocks and some valuation concerns.
- Jun 18, 2026
Moderna shares rose after an FDA advisory committee voted unanimously 9-0 in favor of its mRNA-1010 (mFlusiva) flu vaccine for older adults, ahead of an August 5, 2026 decision.
Daily moves with the verified reason behind them. Education only — not investment advice.
On MarketChacha
Posts about MRNA- Why is Moderna up ~10% today with no news at all?c/usmarkets · 9/17/2026▲ 0
- US Market Brief — Sep 03, 2026 | Futures, movers & what to watchc/us-daily · 9/3/2026▲ 0
- Why did BioNTech (BNTX) drop ~8%? Its cancer vaccine failed the one test that was hardest to passc/usmarkets · 8/30/2026▲ 0
- c/us-daily · 8/26/2026▲ 0
- c/us-daily · 8/21/2026▲ 0
- c/us-daily · 8/20/2026▲ 0
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $1.9B | $-2.8B | -7.26 | -145.2% | -32.6% |
| FY2024 | $3.2B | $-3.6B | -9.28 | -110.0% | -32.7% |
| FY2023 | $6.8B | $-4.7B | -12.33 | -68.8% | -34.0% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $145.0M | $-782.0M | -1.97 | -539.3% |
| 2026Q1 | $389.0M | $-1.3B | -3.40 | -345.2% |
| 2025Q3 | $1.0B | $-200.0M | -0.51 | -19.7% |
| 2025Q2 | $142.0M | $-825.0M | -2.13 | -581.0% |
| 2025Q1 | $108.0M | $-971.0M | -2.52 | -899.1% |
| 2024Q3 | $1.9B | $13.0M | 0.03 | 0.7% |
| 2024Q2 | $241.0M | $-1.3B | -3.33 | -530.7% |
| 2024Q1 | $167.0M | $-1.2B | -3.07 | -703.6% |
| 2023Q3 | $1.8B | $-3.6B | -9.53 | -198.3% |
| 2023Q2 | $344.0M | $-1.4B | -3.62 | -401.2% |
| 2023Q1 | $1.9B | $79.0M | 0.19 | 4.2% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC7/31/2026
- SEC7/31/2026material
- SEC7/8/2026material
- SEC5/11/2026material
- SEC5/1/2026material
- SEC5/1/2026
- SEC3/5/2026material
- SEC2/20/2026
- SEC2/13/2026material
- SEC2/11/2026material
- SEC1/12/2026material
- SEC1/5/2026material
2025
- SEC11/24/2025material
- SEC11/20/2025material
- SEC11/13/2025material
- SEC11/6/2025material
- SEC11/6/2025
- SEC8/1/2025material
- SEC8/1/2025
In the news
- Moderna Stock Is Surging: What's Going On?benzinga.com · 9/17/2026
- Why is Moderna stock surging today? By Investing.comInvesting.com UK · 9/17/2026
- Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher24/7 Wall St. · 9/17/2026
- Moderna stock gains as insider sales and guidance stay in viewad-hoc-news.de · 9/17/2026
- Stephen Hoge Sells 40,294 Shares of Moderna (NASDAQ:MRNA) StockMarketBeat · 9/16/2026
- Moderna stock edges lower as insider sales follow recent trial optimismad-hoc-news.de · 9/16/2026
- Moderna (NASDAQ:MRNA) Stock Price Down 2% Following Insider SellingMarketBeat · 9/15/2026
- Moderna Inc. stock holds recent gains after insider sale plans emergead-hoc-news.de · 9/15/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.